摘要
目的探讨小细胞肺癌（SCLC）患者外周血中髓样抑制细胞（MDSCs）的表达情况及临床意义。方法采用流式细胞技术，通过抗CDllb、CD33、CDl4、HLA-DR等不同荧光抗体组合鉴定SCLC患者外周血中MDSCs的细胞表面标志，分析MDSCs水平与SCLC临床病理特征的相关性。结果36例SCLC患者外周血中存在MDSCs，其特征性细胞表面标志为CDllb^＋CD33^＋HLA-DR^-，其细胞形态属于单个核细胞。SCLC患者和健康对照者外周血单个核细胞群中CDllb^＋CD33^＋HLA-DR^-细胞（MDSCs）比例分别为（26．87±6．87）％和（11．04±3．76）％，差异有统计学意义（P〈0．001）。MDSCs的表达水平与SCLC临床分期、肿瘤转移和治疗情况有关（均P〈0．05），而与患者年龄、性别、吸烟状况及体力状态无关。肿瘤临床分期越晚，MDSCs水平越高（r=0．665，P〈0．001）；伴有远处器官转移的患者，MDSCs水平越高（r=0．489，P=0．003）。SCLC患者治疗后的MDSCs水平低于治疗前水平，差异具有统计学意义（P=0．003）。结论SCLC患者外周血中存在MDSCs；MDSCs水平与SCLC临床分期、肿瘤转移和治疗情况有相关性。MDSCs可能作为一种新的生物标志物辅助SCLC患者的旦期筛查和预后判断．
Objective To explore the presence, frequency and clinical value of myeloid-derived suppressor cells （MDSCs） in peripheral blood of patients with small cell lung cancer （SCLC）. Methods Flow cytometry using antibodies against CD11b, CD33, CD14 or HLA-DR was conducted to explore the unique cell surface markers of MDSCs and statistical analysis was performed to explore the correlation of MDSCs and clinical features. Results MDSCs were present in 36 patients with SCLC and uniquely marked by CD11b and CD33-positive, but HLA-DR-negative on cell surfaces and possessed mononuelear phenotype. The levels of CDllb^＋ CD33^＋HLA-DR^-cells （MDSCs） in the SCLC patients and heahhy controls were （26.87 ± 6.87） % and （11.04 ± 3.76 ）%, respectively, with a statistically significant difference （P 〈 0.001 ）. MDSCs level was significantly associated with clinical stage and tumor distant metastasis （P 〈 0. 05）, but not with age, sex, smoking status and performance status. The later was the clinical stage, the higher was the MDSCs level （r =0. 665, P 〈 0. 001 ）. The level of MDSCs was higher in SCLC patients with distant metastasis than in those without metastasis （ r = 0.489, P = 0. 003 ）. The level of MDSCs was higher before treatment than after treatment and the difference was statisticaUy significant （P = 0. 003）. Conclusions The results of our study demonstrate the existence of MDSCs in SCLC patients and the MDSCs level is associated with SCLC stage, metastasis and treatments. MDSCs might be a novel biomarker for early diagnosis and prognosis for SCLC patients.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2014年第8期592-596,共5页
Chinese Journal of Oncology
基金
国家自然科学基金（81150036）
关键词
肺肿瘤
髓样抑制细胞
普查
预后
Lung neoplasms
Myeloid-derived suppressor cells
Mass screening
Prognosis
